AI-Powered Smart Glasses Win £1M Prize for Dementia Assistance Technology
Key Takeaways
- ▸CrossSense's AI-powered smart glasses won a £1M Longitude Prize for dementia assistance technology, with product availability expected in early 2027
- ▸Pilot studies demonstrated 82% accuracy in household item identification with the glasses versus 46% without, with benefits persisting one hour after removal
- ▸The Wispy AI assistant provides real-time task guidance through verbal cues, floating text, and conversational support tailored to individual user needs via machine learning
Summary
CrossSense Ltd has won the prestigious Longitude Prize on dementia worth £1 million for its AI software embedded in smart glasses designed to help people with dementia maintain independence. The technology, built into frames equipped with a camera, microphone, and speakers, features an AI assistant called Wispy that provides real-time verbal cues, floating text prompts, and conversational support to guide wearers through daily tasks. A pilot study involving 23 pairs of people with dementia and their carers showed significant improvements, with participants able to correctly identify 82% of household items while wearing the glasses compared to just 46% without them—with benefits persisting even after removal.
CrossSense Ltd plans to launch a smartphone version by the end of 2025 and smart glasses-enabled version in early 2027, with subscriptions expected to cost around £50 per month and glasses up to £1,000. The company intends to initially market directly to consumers before seeking NHS integration. The prize funding will support a four-week pilot program in people's homes during the last quarter of 2026, with the technology utilizing machine learning to adapt to individual users' changing needs and care requirements.
- The technology is expected to cost £50/month subscription plus up to £1,000 for smart glasses, with eventual NHS integration planned
Editorial Opinion
CrossSense's breakthrough in assistive technology represents a meaningful advancement in dementia care, moving beyond simple reminders to deliver real-time, adaptive task guidance. While the preliminary results are encouraging and show concrete cognitive benefits, the company wisely plans additional controlled trials before broader deployment—a responsible approach that acknowledges the need for rigorous validation in healthcare. However, important questions around user consent, data privacy, and long-term adoption rates in real-world settings remain to be addressed as the technology moves toward commercial launch.
